Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Wang, Xiaolu ^a   Gao, Haitao ^a   Ren, Lixin ^a   Gu, Junfei ^a   Zhang, Yanping ^a   Zhang, Yong ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

5 Aza 2' deoxycytidine (5 Aza CdR); Castration; DNA methyltransferases (DNMTs); miR 146a; Prostate cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 146A; AZACITIDINE; METHYLTRANSFERASE; MICRORNA; MIRN146 MICRORNA, HUMAN;

ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL VIABILITY; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; LNCAP CELL LINE; MALE; MOUSE; MTS ASSAY; NONHUMAN; NUCLEOTIDE BINDING SITE; PATHOGENESIS; PC3 CELL LINE; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DNA METHYLATION; HUMANS; MALE; METHYLTRANSFERASES; MICE; MICRORNAS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900860388     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-308     Document Type: Article

References (33)

1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008, 15(1):3866-3871. 2706483, 18304396.
2. Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 Years' follow-Up. Mol Urol 1999, 3(3):287-292.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
4. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, Arsov C, Visakorpi T, Borre M, Hoyer S, Orntoft TF, Sørensen KD. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol 2013, 31(26):3250-3258. 10.1200/JCO.2012.47.1847, 23918943.
5. Patra SK, Bettuzzi S. Epigenetic DNA-(cytosine-5-carbon) modifications: 5-aza-2'-deoxycytidine and DNA-demethylation. Biochemistry Biokhimiia 2009, 74(6):613-619. 10.1134/S0006297909060042, 19645665.
6. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 2008, 68(2):210-222. 10.1002/pros.20673, 18092350.
7. Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa Y, Mizokami A, Ito H, Yatani R, Shiraishi T. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 2000, 80(12):1789-1796. 10.1038/labinvest.3780190, 11140692.
8. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, Day ML. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 2006, 66(1):385-392. 10.1158/0008-5472.CAN-05-2020, 16397253.
9. Zorn CS, Wojno KJ, McCabe MT, Kuefer R, Gschwend JE, Day ML. 5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res 2007, 13(7):2136-2143. 10.1158/1078-0432.CCR-06-2381, 17404097.
10. Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V, Pinto A, Gattei V, Maio M. 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. Blood 2003, 101(11):4644-4646. discussion 4645-4646, 10.1182/blood-2002-11-3458, 12756166.
11. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103(5):1635-1640. 10.1182/blood-2003-03-0687, 14604977.
12. Hurtubise A, Momparler RL. Evaluation of antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. Anti-Cancer Drugs 2004, 15(2):161-167.
13. Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One 2011, 6(9):e25634. 10.1371/journal.pone.0025634, 3182253, 21980513.
14. Fang X, Zheng C, Liu Z, Ekman P, Xu D. Enhanced sensitivity of prostate cancer DU145 cells to cisplatinum by 5-aza-2'-deoxycytidine. Oncol Rep 2004, 12(3):523-526.
15. Schott G, Mari-Ordonez A, Himber C, Alioua A, Voinnet O, Dunoyer P. Differential effects of viral silencing suppressors on siRNA and miRNA loading support the existence of two distinct cellular pools of ARGONAUTE1. EMBO J 2012, 31(11):2553-2565. 10.1038/emboj.2012.92, 3365429, 22531783.
16. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27(12):1788-1793. 10.1038/sj.onc.1210809, 17891175.
17. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA 2008, 14(3):417-424. 10.1261/rna.874808, 2248249, 18174313.
18. Lin SL, Chang D, Ying SY. Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis 2007, 28(2):310-320.
19. Jiang M, Zhang Y, Fei J, Chang X, Fan W, Qian X, Zhang T, Lu D. Rapid quantification of DNA methylation by measuring relative peak heights in direct bisulfite-PCR sequencing traces. Lab Invest 2010, 90(2):282-290. 10.1038/labinvest.2009.132, 20010852.
20. Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R. Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol 2011, 18(5):5875-5883.
21. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004, 32(3):e38. 10.1093/nar/gnh032, 373427, 14973332.
22. Lukiw WJ, Zhao Y, Cui JG. An NF-kappaB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 2008, 283(46):31315-31322. 10.1074/jbc.M805371200, 2581572, 18801740.
23. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006, 103(33):12481-12486. 10.1073/pnas.0605298103, 1567904, 16885212.
24. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001, 61(9):3550-3555.
25. Andriole GL. Overview of pivotal studies for prostate cancer risk reduction, past and present. Urology 2009, 73(5 Suppl):S36-S43.
26. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005, 97(2):103-115. 10.1093/jnci/dji010, 15657340.
27. Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D. A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 1998, 84(1):87-89.
28. Shang D, Liu Y, Liu Q, Zhang F, Feng L, Lv W, Tian Y. Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Lett 2009, 278(1):82-87. 10.1016/j.canlet.2008.12.034, 19168279.
29. Joly-Pharaboz MO, Kalach JJ, Pharaboz J, Chantepie J, Nicolas B, Baille ML, Ruffion A, Benahmed M, Andre J. Androgen inhibits the growth of carcinoma cell lines established from prostate cancer xenografts that escape androgen treatment. J Steroid Biochem Mol Biol 2008, 111(1-2):50-59.
30. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999, 5(10):2891-2898.
31. Reik W, Kelsey G, Walter J. Dissecting de novo methylation. Nat Genet 1999, 23(4):380-382. 10.1038/70476, 10581015.
32. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000, 9(16):2395-2402. 10.1093/hmg/9.16.2395, 11005794.
33. Lee JY, Jeong W, Lim W, Lim CH, Bae SM, Kim J, Bazer FW, Song G. Hypermethylation and post-transcriptional regulation of DNA methyltransferases in the ovarian carcinomas of the laying hen. PLoS One 2013, 8(4):e61658. 10.1371/journal.pone.0061658, 3629126, 23613894.